NO782341L - Fremgangsmaate for fremstilling av farmakologisk aktive n-pyrimidinyl-imidsyreestere - Google Patents
Fremgangsmaate for fremstilling av farmakologisk aktive n-pyrimidinyl-imidsyreestereInfo
- Publication number
- NO782341L NO782341L NO782341A NO782341A NO782341L NO 782341 L NO782341 L NO 782341L NO 782341 A NO782341 A NO 782341A NO 782341 A NO782341 A NO 782341A NO 782341 L NO782341 L NO 782341L
- Authority
- NO
- Norway
- Prior art keywords
- methoxy
- ethyl
- hydrogen
- pyrimidin
- amino
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 15
- 238000002360 preparation method Methods 0.000 title claims abstract description 8
- 239000001257 hydrogen Substances 0.000 claims description 22
- 229910052739 hydrogen Inorganic materials 0.000 claims description 22
- 150000002431 hydrogen Chemical class 0.000 claims description 19
- 150000001875 compounds Chemical class 0.000 claims description 16
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 15
- 238000004519 manufacturing process Methods 0.000 claims description 13
- 239000007858 starting material Substances 0.000 claims description 12
- 239000002253 acid Substances 0.000 claims description 11
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 10
- 150000002148 esters Chemical class 0.000 claims description 8
- -1 N-[4-amino-5-(3,4,5-trimethoxybenzyl)-pyrimidin-2-yl]-butyrimidic acid ethyl ester Chemical compound 0.000 claims description 7
- 125000000217 alkyl group Chemical group 0.000 claims description 6
- 125000004432 carbon atom Chemical group C* 0.000 claims description 6
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 5
- 239000002904 solvent Substances 0.000 claims description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 2
- 230000003197 catalytic effect Effects 0.000 claims description 2
- 239000000460 chlorine Substances 0.000 claims description 2
- 229910052801 chlorine Inorganic materials 0.000 claims description 2
- XAEXEPVKHZFXPC-UHFFFAOYSA-N ethyl N-[4-amino-5-(4-chlorophenyl)-6-ethylpyrimidin-2-yl]ethanimidate Chemical compound C(C)OC(C)=NC1=NC(=C(C(=N1)N)C1=CC=C(C=C1)Cl)CC XAEXEPVKHZFXPC-UHFFFAOYSA-N 0.000 claims description 2
- SZQPEQWJSHHWNX-UHFFFAOYSA-N ethyl N-[4-amino-5-[(3,4,5-trimethoxyphenyl)methyl]pyrimidin-2-yl]-2-methylpropanimidate Chemical compound C(C)OC(C(C)C)=NC1=NC=C(C(=N1)N)CC1=CC(=C(C(=C1)OC)OC)OC SZQPEQWJSHHWNX-UHFFFAOYSA-N 0.000 claims description 2
- QHACXHKLEYMANN-UHFFFAOYSA-N ethyl N-[4-amino-5-[(3,4,5-trimethoxyphenyl)methyl]pyrimidin-2-yl]ethanimidate Chemical compound C(C)OC(C)=NC1=NC=C(C(=N1)N)CC1=CC(=C(C(=C1)OC)OC)OC QHACXHKLEYMANN-UHFFFAOYSA-N 0.000 claims description 2
- ZPYLFXDWHKTTTN-UHFFFAOYSA-N ethyl N-[4-amino-5-[(3,4,5-trimethoxyphenyl)methyl]pyrimidin-2-yl]propanimidate Chemical compound C(C)OC(CC)=NC1=NC=C(C(=N1)N)CC1=CC(=C(C(=C1)OC)OC)OC ZPYLFXDWHKTTTN-UHFFFAOYSA-N 0.000 claims description 2
- HLUTYBKXXUTNEY-UHFFFAOYSA-N ethyl N-[4-amino-5-[(4-methoxyphenyl)methyl]pyrimidin-2-yl]ethanimidate Chemical compound C(C)OC(C)=NC1=NC=C(C(=N1)N)CC1=CC=C(C=C1)OC HLUTYBKXXUTNEY-UHFFFAOYSA-N 0.000 claims description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 150000004702 methyl esters Chemical class 0.000 claims 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 description 14
- NDQXKKFRNOPRDW-UHFFFAOYSA-N 1,1,1-triethoxyethane Chemical compound CCOC(C)(OCC)OCC NDQXKKFRNOPRDW-UHFFFAOYSA-N 0.000 description 9
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 9
- 229960001082 trimethoprim Drugs 0.000 description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- WKSAUQYGYAYLPV-UHFFFAOYSA-N pyrimethamine Chemical compound CCC1=NC(N)=NC(N)=C1C1=CC=C(Cl)C=C1 WKSAUQYGYAYLPV-UHFFFAOYSA-N 0.000 description 6
- 229940124530 sulfonamide Drugs 0.000 description 5
- 150000003456 sulfonamides Chemical class 0.000 description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- KBBNFTOXDUKKGX-UHFFFAOYSA-N 2-amino-n-(4,5-dimethyl-1,3-oxazol-2-yl)benzenesulfonamide Chemical compound O1C(C)=C(C)N=C1NS(=O)(=O)C1=CC=CC=C1N KBBNFTOXDUKKGX-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- FGWYWKIOMUZSQF-UHFFFAOYSA-N 1,1,1-triethoxypropane Chemical compound CCOC(CC)(OCC)OCC FGWYWKIOMUZSQF-UHFFFAOYSA-N 0.000 description 2
- HDPNBNXLBDFELL-UHFFFAOYSA-N 1,1,1-trimethoxyethane Chemical compound COC(C)(OC)OC HDPNBNXLBDFELL-UHFFFAOYSA-N 0.000 description 2
- 241000193985 Streptococcus agalactiae Species 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 150000002463 imidates Chemical class 0.000 description 2
- 239000013558 reference substance Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- KOPMZTKUZCNGFY-UHFFFAOYSA-N 1,1,1-triethoxybutane Chemical compound CCCC(OCC)(OCC)OCC KOPMZTKUZCNGFY-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- OPMKWMZUBTUNEX-UHFFFAOYSA-N 2-amino-n-(5-methyl-1,2-oxazol-3-yl)benzenesulfonamide Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C(=CC=CC=2)N)=N1 OPMKWMZUBTUNEX-UHFFFAOYSA-N 0.000 description 1
- MTRRRDFGNMVWQW-UHFFFAOYSA-N 2-amino-n-(5-methylpyrimidin-2-yl)benzenesulfonamide Chemical compound N1=CC(C)=CN=C1NS(=O)(=O)C1=CC=CC=C1N MTRRRDFGNMVWQW-UHFFFAOYSA-N 0.000 description 1
- CWSYFKKTOAFUJX-UHFFFAOYSA-N 3-amino-n-(2-phenylpyrazol-3-yl)benzenesulfonamide Chemical compound NC1=CC=CC(S(=O)(=O)NC=2N(N=CC=2)C=2C=CC=CC=2)=C1 CWSYFKKTOAFUJX-UHFFFAOYSA-N 0.000 description 1
- XPGJOCWCEGOGMR-UHFFFAOYSA-N 3-amino-n-(6-chloropyridazin-3-yl)benzenesulfonamide Chemical compound NC1=CC=CC(S(=O)(=O)NC=2N=NC(Cl)=CC=2)=C1 XPGJOCWCEGOGMR-UHFFFAOYSA-N 0.000 description 1
- CKKVFDQYOWXYQH-UHFFFAOYSA-N 5-[(2,4-dichlorophenyl)methyl]pyrimidine-2,4-diamine Chemical compound NC1=NC(N)=NC=C1CC1=CC=C(Cl)C=C1Cl CKKVFDQYOWXYQH-UHFFFAOYSA-N 0.000 description 1
- YFXPEDMBLISFPG-UHFFFAOYSA-N 5-[(3,4-dichlorophenyl)methyl]pyrimidine-2,4-diamine Chemical compound NC1=NC(N)=NC=C1CC1=CC=C(Cl)C(Cl)=C1 YFXPEDMBLISFPG-UHFFFAOYSA-N 0.000 description 1
- KNMBSJCWXZMBIJ-UHFFFAOYSA-N 5-[(4-chlorophenyl)methyl]pyrimidine-2,4-diamine Chemical compound NC1=NC(N)=NC=C1CC1=CC=C(Cl)C=C1 KNMBSJCWXZMBIJ-UHFFFAOYSA-N 0.000 description 1
- YMGUVTBVYOGUFZ-UHFFFAOYSA-N 5-[(4-methoxyphenyl)methyl]pyrimidine-2,4-diamine Chemical compound C1=CC(OC)=CC=C1CC1=CN=C(N)N=C1N YMGUVTBVYOGUFZ-UHFFFAOYSA-N 0.000 description 1
- ZGWAEUUYBLJLPE-UHFFFAOYSA-N 5-[(4-methylphenyl)methyl]pyrimidine-2,4-diamine Chemical compound C1=CC(C)=CC=C1CC1=CN=C(N)N=C1N ZGWAEUUYBLJLPE-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000005141 Otitis Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- PJSFRIWCGOHTNF-UHFFFAOYSA-N Sulphormetoxin Chemical compound COC1=NC=NC(NS(=O)(=O)C=2C=CC(N)=CC=2)=C1OC PJSFRIWCGOHTNF-UHFFFAOYSA-N 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- LDBTVAXGKYIFHO-UHFFFAOYSA-N diaveridine Chemical compound C1=C(OC)C(OC)=CC=C1CC1=CN=C(N)N=C1N LDBTVAXGKYIFHO-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 208000019258 ear infection Diseases 0.000 description 1
- CZRMBBRECCVWBQ-UHFFFAOYSA-N ethyl N-[4-amino-5-(4-chlorophenyl)-6-ethylpyrimidin-2-yl]-2-phenylethanimidate Chemical compound C(C)OC(CC1=CC=CC=C1)=NC1=NC(=C(C(=N1)N)C1=CC=C(C=C1)Cl)CC CZRMBBRECCVWBQ-UHFFFAOYSA-N 0.000 description 1
- ZYBLUYXQJHLOPR-UHFFFAOYSA-N ethyl N-[4-amino-5-(4-chlorophenyl)-6-ethylpyrimidin-2-yl]propanimidate Chemical compound C(C)OC(CC)=NC1=NC(=C(C(=N1)N)C1=CC=C(C=C1)Cl)CC ZYBLUYXQJHLOPR-UHFFFAOYSA-N 0.000 description 1
- JMHJAYHRTQYXTC-UHFFFAOYSA-N ethyl N-[4-amino-5-[(2,4-dichlorophenyl)methyl]pyrimidin-2-yl]ethanimidate Chemical compound C(C)OC(C)=NC1=NC=C(C(=N1)N)CC1=C(C=C(C=C1)Cl)Cl JMHJAYHRTQYXTC-UHFFFAOYSA-N 0.000 description 1
- FRAOBKLFMTWRNA-UHFFFAOYSA-N ethyl N-[4-amino-5-[(4-chlorophenyl)methyl]pyrimidin-2-yl]ethanimidate Chemical compound C(C)OC(C)=NC1=NC=C(C(=N1)N)CC1=CC=C(C=C1)Cl FRAOBKLFMTWRNA-UHFFFAOYSA-N 0.000 description 1
- LIELPDLLCQTTAC-UHFFFAOYSA-N ethyl N-[4-amino-5-[(4-methylphenyl)methyl]pyrimidin-2-yl]ethanimidate Chemical compound C(C)OC(C)=NC1=NC=C(C(=N1)N)CC1=CC=C(C=C1)C LIELPDLLCQTTAC-UHFFFAOYSA-N 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000004798 organs belonging to the digestive system Anatomy 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 229960000611 pyrimethamine Drugs 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- SEEPANYCNGTZFQ-UHFFFAOYSA-N sulfadiazine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=NC=CC=N1 SEEPANYCNGTZFQ-UHFFFAOYSA-N 0.000 description 1
- ZZORFUFYDOWNEF-UHFFFAOYSA-N sulfadimethoxine Chemical compound COC1=NC(OC)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 ZZORFUFYDOWNEF-UHFFFAOYSA-N 0.000 description 1
- BRBKOPJOKNSWSG-UHFFFAOYSA-N sulfaguanidine Chemical compound NC(=N)NS(=O)(=O)C1=CC=C(N)C=C1 BRBKOPJOKNSWSG-UHFFFAOYSA-N 0.000 description 1
- 229960004257 sulfaguanidine Drugs 0.000 description 1
- QPPBRPIAZZHUNT-UHFFFAOYSA-N sulfamerazine Chemical compound CC1=CC=NC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 QPPBRPIAZZHUNT-UHFFFAOYSA-N 0.000 description 1
- ASWVTGNCAZCNNR-UHFFFAOYSA-N sulfamethazine Chemical compound CC1=CC(C)=NC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 ASWVTGNCAZCNNR-UHFFFAOYSA-N 0.000 description 1
- KXRZBTAEDBELFD-UHFFFAOYSA-N sulfamethopyrazine Chemical compound COC1=NC=CN=C1NS(=O)(=O)C1=CC=C(N)C=C1 KXRZBTAEDBELFD-UHFFFAOYSA-N 0.000 description 1
- GPTONYMQFTZPKC-UHFFFAOYSA-N sulfamethoxydiazine Chemical compound N1=CC(OC)=CN=C1NS(=O)(=O)C1=CC=C(N)C=C1 GPTONYMQFTZPKC-UHFFFAOYSA-N 0.000 description 1
- VLYWMPOKSSWJAL-UHFFFAOYSA-N sulfamethoxypyridazine Chemical compound N1=NC(OC)=CC=C1NS(=O)(=O)C1=CC=C(N)C=C1 VLYWMPOKSSWJAL-UHFFFAOYSA-N 0.000 description 1
- IZOYMGQQVNAMHS-UHFFFAOYSA-N sulfametrole Chemical compound COC1=NSN=C1NS(=O)(=O)C1=CC=C(N)C=C1 IZOYMGQQVNAMHS-UHFFFAOYSA-N 0.000 description 1
- GECHUMIMRBOMGK-UHFFFAOYSA-N sulfapyridine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=CC=CC=N1 GECHUMIMRBOMGK-UHFFFAOYSA-N 0.000 description 1
- JNMRHUJNCSQMMB-UHFFFAOYSA-N sulfathiazole Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=NC=CS1 JNMRHUJNCSQMMB-UHFFFAOYSA-N 0.000 description 1
- YZMCKZRAOLZXAZ-UHFFFAOYSA-N sulfisomidine Chemical compound CC1=NC(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 YZMCKZRAOLZXAZ-UHFFFAOYSA-N 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
- C07D239/49—Two nitrogen atoms with an aralkyl radical, or substituted aralkyl radical, attached in position 5, e.g. trimethoprim
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Tropical Medicine & Parasitology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19772730468 DE2730468A1 (de) | 1977-07-06 | 1977-07-06 | Neue n-pyrimidinyl-imidsaeureester, verfahren zu ihrer herstellung und diese enthaltende arzneimittel |
Publications (1)
Publication Number | Publication Date |
---|---|
NO782341L true NO782341L (no) | 1979-01-09 |
Family
ID=6013253
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO782341A NO782341L (no) | 1977-07-06 | 1978-07-05 | Fremgangsmaate for fremstilling av farmakologisk aktive n-pyrimidinyl-imidsyreestere |
Country Status (15)
Country | Link |
---|---|
US (1) | US4315931A (fr) |
EP (1) | EP0000335B1 (fr) |
JP (1) | JPS5416483A (fr) |
AR (1) | AR220139A1 (fr) |
AT (1) | AT360998B (fr) |
AU (1) | AU515679B2 (fr) |
CA (1) | CA1107733A (fr) |
DE (2) | DE2730468A1 (fr) |
DK (1) | DK142577C (fr) |
FI (1) | FI782174A (fr) |
HU (1) | HU178177B (fr) |
IE (1) | IE47013B1 (fr) |
IL (1) | IL55020A (fr) |
NO (1) | NO782341L (fr) |
ZA (1) | ZA783874B (fr) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3045720A1 (de) * | 1980-12-04 | 1982-07-08 | Basf Ag, 6700 Ludwigshafen | N-pyrimidinyl-carbaminsaeureester, verfahren zu ihrer herstellung und diese enthaltende arzneimittel |
US4767443A (en) * | 1984-09-20 | 1988-08-30 | Ciba-Geigy Corporation | Antifungal and antibacterial diazine derivatives compositions, intermediates, and method of use therefor |
CH668969A5 (de) * | 1986-09-05 | 1989-02-15 | Ciba Geigy Ag | Verfahren zur bekaempfung unerwuenschten pflanzenwuchses sowie zur regulierung des pflanzenwachstums. |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3049544A (en) * | 1962-08-14 | Method for the preparation of | ||
DE2732029A1 (de) * | 1977-07-15 | 1979-02-01 | Basf Ag | Neue amidino-benzylpyrimidine, verfahren zu ihrer herstellung und diese enthaltende arzneimittel |
-
1977
- 1977-07-06 DE DE19772730468 patent/DE2730468A1/de not_active Withdrawn
-
1978
- 1978-06-05 FI FI782174A patent/FI782174A/fi not_active Application Discontinuation
- 1978-06-19 EP EP78100183A patent/EP0000335B1/fr not_active Expired
- 1978-06-19 DE DE7878100183T patent/DE2861128D1/de not_active Expired
- 1978-06-27 IL IL55020A patent/IL55020A/xx unknown
- 1978-06-28 IE IE1292/78A patent/IE47013B1/en unknown
- 1978-06-30 AU AU37643/78A patent/AU515679B2/en not_active Expired
- 1978-07-03 US US06/921,701 patent/US4315931A/en not_active Expired - Lifetime
- 1978-07-04 AR AR272832A patent/AR220139A1/es active
- 1978-07-04 HU HU78BA3671A patent/HU178177B/hu unknown
- 1978-07-05 NO NO782341A patent/NO782341L/no unknown
- 1978-07-05 CA CA306,847A patent/CA1107733A/fr not_active Expired
- 1978-07-05 DK DK303278A patent/DK142577C/da active
- 1978-07-05 ZA ZA00783874A patent/ZA783874B/xx unknown
- 1978-07-05 AT AT487678A patent/AT360998B/de not_active IP Right Cessation
- 1978-07-06 JP JP8153178A patent/JPS5416483A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
IL55020A0 (en) | 1978-08-31 |
US4315931A (en) | 1982-02-16 |
IE781292L (en) | 1979-01-06 |
ATA487678A (de) | 1980-07-15 |
DE2730468A1 (de) | 1979-01-18 |
AR220139A1 (es) | 1980-10-15 |
CA1107733A (fr) | 1981-08-25 |
HU178177B (en) | 1982-03-28 |
FI782174A (fi) | 1979-01-07 |
EP0000335B1 (fr) | 1981-10-07 |
ZA783874B (en) | 1979-08-29 |
DE2861128D1 (en) | 1981-12-17 |
DK142577B (da) | 1980-11-24 |
JPS5416483A (en) | 1979-02-07 |
DK303278A (da) | 1979-01-07 |
IL55020A (en) | 1981-11-30 |
EP0000335A1 (fr) | 1979-01-24 |
DK142577C (da) | 1981-07-20 |
AU3764378A (en) | 1980-01-03 |
AT360998B (de) | 1981-02-10 |
AU515679B2 (en) | 1981-04-16 |
IE47013B1 (en) | 1983-11-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK172884B1 (da) | Analogifremgangsmåde til fremstilling af i 5-stilling substituerede 2,4-diaminopyrimidiner og mellemprodukter til anvendels | |
US10590145B2 (en) | Tetrahydrothiopyranopyrimidine derivatives as anti-HIV agent | |
DE102005062742A1 (de) | Sulfoximin substituierte Pyrimidine, Verfahren zu deren Herstellung und ihre Verwendung als Arzneimittel | |
JP2012506391A (ja) | Cdkインヒビターとしてのスルホキシミン−置換されたアニリノ−ピリミジン誘導体類、それらの製造及び医薬製剤としてのそれらの使用 | |
Falco et al. | 2, 4-Diaminopyrimidines as Antimalarials. I. 1 5-Aryloxyl and 5-Alkoxyl Derivatives | |
CN109053591A (zh) | 含联苯结构的二芳基嘧啶类衍生物及其制备方法和用途 | |
WO2008022725A1 (fr) | Acides spirotétroniques à substitution biphényle et leur utilisation pour le traitement de maladies rétrovirales | |
US5151427A (en) | Anthelminitics | |
US11447501B2 (en) | Biphenyl-containing diarylpyrimido compounds, pharmaceutically-acceptable salts thereof, composition and preparation thereof | |
NO782341L (no) | Fremgangsmaate for fremstilling av farmakologisk aktive n-pyrimidinyl-imidsyreestere | |
US4279899A (en) | Benzylpyrimidines, processes for their manufacture, and drugs containing the said compounds | |
US4189581A (en) | 2-Acylamino-4-amino-5-(3,4,5-trimethoxybenzyl)-pyrimidines | |
DK160251B (da) | Analogifremgangsmaade til fremstilling af substituerede anthra(1,9-cd)pyrazol-6(2h)-oner | |
NO782455L (no) | Fremgangsmaate for fremstilling av farmakologisk aktive amidino-benzylpyrimidiner | |
US7371758B2 (en) | Antimalarial pyrimidine derivatives and methods of making and using them | |
US4333936A (en) | Novel amidino-benzylpyrimidines, processes for their manufacture and antibacterial and antiprotozoal use thereof | |
KR820001338B1 (ko) | 벤질 피리미딘의 제조방법 | |
US3787409A (en) | 2,4-diamino-5-(3-alkoxy-4,5-methylenedioxybenzyl)pyrimidine | |
US4073786A (en) | 2-Amino-4-hydroxy-6-hydroxymethyl-7,7-diethyl-7,8-dihydropteridine and the 7-spirocyclohexyl analogue thereof | |
NO161102B (no) | Lokkemat for gnagere omfattende foede og en gift. | |
EP0006987A1 (fr) | 2,4-Diamino-5-benzylpyrimidines, notamment pour le traitement médical d'infections microbiennes, compositions pharmaceutiques contenant ces composés et procédé pour la préparation de ces derniers | |
RU2419431C1 (ru) | ПРОИЗВОДНЫЕ β-КАРБОЛИНА, ОБЛАДАЮЩИЕ ПРОТИВОТУБЕРКУЛЕЗНОЙ АКТИВНОСТЬЮ, ИХ ПРИМЕНЕНИЯ ДЛЯ ПРОИЗВОДСТВА ЛЕКАРСТВЕННОГО СРЕДСТВА, СПОСОБ ИХ СИНТЕЗА, А ТАКЖЕ НОВЫЕ МЕТОДЫ ЛЕЧЕНИЯ С ИХ ИСПОЛЬЗОВАНИЕМ | |
Haque | Synthesis of 6-substituted pyrimidine from ortic acid | |
JP2001316376A (ja) | アニライド化合物及び除草剤 | |
JP5175742B2 (ja) | 抗菌及び抗腫瘍特性を有する新規マクロライド化合物 |